Alfacell Expands Onconase Clinical Program

Alfacell, a leader and pioneer in the research, development and commercialization of ribonucleases for the treatment of cancer and other therapeutic applications, has initiated a multicenter, open-label, Phase I/II trial to evaluate Onconase in patients with refractory non-small cell lung cancer.

"This new study is designed to assess the therapeutic potential of Onconase [ranpirnase] in a population that has shown a resistance to other treatments, and to evaluate a new schedule of administration," said Kuslima Shogen, CEO of Alfacell. "The results obtained from Part 1 of this trial will be used to expand our clinical program in the initiation of Phase II trials in esophageal and refractory breast cancers."